Atherosclerotic Cardiovascular Disease Market Epidemiology Report, Size, Share, Trends and Forecast 2025-2035

According to the IMARC Group, the atherosclerotic cardiovascular disease market size reached a value of USD 24.0 Billion in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 32.3 Billion by 2035, exhibiting a growth rate (CAGR) of 2.8% during 2025-2035. An emerging trend favoring regenerative medicines exist because they have the potential of fixing the injured blood vessels and cardiac tissues.

ASCVD is essentially a very common cardiovascular pathology characterized by an elaborate buildup of plaques within arteries, causing detrimental reductions in blood flow and eventual occlusions. The atherosclerotic cardiovascular disease market is currently booming upon the rising number of risk factors, including hypertension, diabetes, obesity, and lifestyle preferences that remain largely sedentary, all acting synergistically to cause increased demand for appropriate diagnostic and treatment options. Besides this, advancements in pharmaceutical research have led to the development of innovative lipid-lowering drugs, including PCSK9 inhibitors, bempedoic acid, and inclisiran, which offer improved efficacy in managing cholesterol levels and reducing cardiovascular risks, further augmenting the atherosclerotic cardiovascular disease market expansion. The growing adoption of combination therapies, such as statins with ezetimibe or other adjuncts, is enhancing treatment outcomes and adherence.

Moreover, governmental and non-governmental initiatives aimed at raising awareness about ASCVD prevention and management are also stimulating the atherosclerotic cardiovascular disease market growth. Technological advancements in diagnostic tools, including high-sensitivity cardiac troponin tests and coronary artery calcium scoring, are enabling early detection and intervention, further supporting the market. Additionally, the integration of digital health technologies, such as wearable devices and mobile applications, is revolutionizing patient monitoring and personalized disease management, enhancing engagement and compliance, thereby catalyzing the atherosclerotic cardiovascular disease market expansion. Furthermore, a significant trend is the increasing emphasis on precision medicine, leveraging genetic and biomarker data to tailor therapeutic strategies, which is expected to bolster the atherosclerotic cardiovascular disease market growth in the coming years.

Request for a sample of this report: https://www.imarcgroup.com/atherosclerotic-cardiovascular-disease-market/requestsample

This report also provides a detailed analysis of the current atherosclerotic cardiovascular disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Competitive Landscape with key players:

The competitive landscape of the atherosclerotic cardiovascular disease market has been studied in the report with the detailed profiles of the key players operating in the market.

1. Agepha Pharma
2. AstraZeneca
3. Lilly
4. NewAmsterdam Pharma

Countries Covered:

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country:

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the hyperuricemia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the hhyperuricemia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145